Autopsy report · NCT00598091

A Phase I/Expansion Study of Dasatinib

“Low accrual, unable to meet endpoint in timely manner”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months after it had already started.
• Ran for about 5 years 1 month before it stopped.
• 30 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Refractory Solid Tumors; Pancreatic Adenocarcinoma

Interventions

gemcitabine; dasatinib; gemcitabine; dasatinib

Participants

30

Sites

3

Countries

United States

Trials that died the same way

• CD8 Reactivity to Microorganisms in Blood and Breast Milk
  “Slow/insufficient accrual” (68% match in meaning)
• Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
  “low accrual not allowing site to meeting statistical endpoints” (65% match in meaning)
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
  “Closed early due to slow accrual” (64% match in meaning)
• Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
  “Low accrual; target accrual not met” (63% match in meaning)
• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.